Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: J Mol Cell Cardiol. 2016 Apr 27;97:106–113. doi: 10.1016/j.yjmcc.2016.04.015

Fig. 5.

Fig. 5

Artesunate blocks cardiac hypertrophy in vivo. (A) Ten week-old mice were subjected to transverse aortic constriction (TAC) and treated with vehicle or artesunate for four weeks. (B–D) Echocardiography revealed that artesunate blunted TAC-induced systolic dysfunction, and reduced TAC-mediated thickening of the LV posterior wall and intraventricular septum. (E) LV weight-to-tibia length ratios were determined at necropsy. (F) Images of LV sections stained with fluorescein-conjugated peanut agglutinin were used to assess myocyte cross-sectional area. Scale bar = 10 mu;m. (G) Quantification of myocyte cross-sectional area (mu;m2); >100 myocytes were quantified per the indicated number of LVs. *P < 0.05 vs. sham; †P < 0.05 vs. TAC + vehicle.